#United States #Robbins Geller #San Diego #Class Action #Hims & Hers

Hims & Hers Health, Inc. Investors: Class Action Lawsuit Opportunity

Recently, Robbins Geller Rudman & Dowd LLP announced crucial information for investors of Hims & Hers Health, Inc. Individuals who purchased or acquired Hims & Hers securities between August 4, 2025, and July 29, 2026, have until November 2, 2026, to seek appointment as lead plaintiff in a class action lawsuit against the company. This lawsuit, titled Velanki v. Hims & Hers Health, Inc., filed in the Northern District of California, accuses the firm and certain executives of violations related to the Securities Exchange Act of 1934, resulting in significant investor losses.

Hims & Hers is a health and wellness platform designed to connect consumers with certified healthcare professionals. However, the allegations detail a troubling pattern of behavior during the class period. It was claimed that Hims & Hers allegedly made misleading statements and failed to disclose critical information regarding how they handled consumers' health data.

The lawsuit claims that the company shared sensitive health information with third-party advertising platforms, which contradicts their promises of maintaining confidentiality. Furthermore, it is alleged that despite conveying to customers that they would have consultations to determine the right treatment, Hims & Hers began charging for prescriptions immediately after submitting an intake form.

These actions are said to have drawn regulatory scrutiny, resulting in additional fees and penalties for the company. In a shocking development, reports emerged that on July 29, 2026, the Federal Trade Commission announced it had filed a suit against Hims & Hers. The FTC accused the company of deceptive practices related to its privacy claims and harmful billing practices, which has further tarnished its reputation among consumers and investors.

As the dust settles, Hims & Hers stock prices dropped significantly—by nearly 15%—due to this negative publicity, leading to further outrage among shareholders.

How to Become a Lead Plaintiff

According to the Private Securities Litigation Reform Act of 1995, any investor who acquired Hims & Hers securities during the class period can apply to be appointed as the lead plaintiff in this class action case. The lead plaintiff is typically the individual with the most substantial financial loss in relation to the class who is also considered competent to represent the interests of the class members.

Being a lead plaintiff is not mandatory for recovering potential damages or a share of any settlement. All investors affected by the alleged misconduct can still recover even if not designated as lead plaintiff.

Robbins Geller Rudman & Dowd is an established leader in representing investors in securities fraud cases, known for its record of recovering billions for its clients. For instance, their work has earned them the top spot on the ISS Securities Class Action Services Top 50 Report multiple times.

Investors wishing to join or inquire about the class action lawsuit are encouraged to contact Robbins Geller at 800-851-7783 or email them directly. Providing your information is crucial to ensure your case is represented.

Conclusion

This ongoing case against Hims & Hers Health, Inc. serves as a poignant reminder of the responsibilities that companies have towards their investors and customers. As the deadline approaches, it's imperative for investors to understand their rights and potential recourse against companies that have failed to uphold their commitments. If you have been affected by Hims & Hers' alleged practices, take action before the upcoming deadline to secure your position in this critical lawsuit.